Indications
Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age.
Composition
- Active substance
- hydroxycarbamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xromi
- Active substance
- hydroxycarbamide
- ATC code
- L01XX05
- Therapeutic area
- Anemia, Sickle Cell
- Marketing authorisation holder
- Lipomed GmbH
- Status
- Authorised
- EU authorisation
- 1 Jul 2019